Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nikoletta Sidiropoulos

Molecular Genetic Pathology Burlington, VT Medical Doctor

NPI 1356446017 CMS profile 515887

111 Colchester Ave, Burlington, VT 05401

Open in the dashboard

General payments

$51,283

58 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nikoletta Sidiropoulos of Burlington, VT is reported in the CMS Open Payments database as having received $51,283 across 58 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $118 2
2024 General $11,851 15
2022 General $1,593 1
2021 General $9,965 12
2020 General $9,518 9
2019 General $18,238 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nikoletta Sidiropoulos
  • Vermont median
  • Middle half of Vermont
  • National median

In program year 2025, general payments to Nikoletta Sidiropoulos were reported at $118. Among 430 Vermont profiles paid that year, the median was $119 and the middle half received between $39 and $763.

Show as a table
Year Nikoletta Sidiropoulos Vermont median Middle half National median
2019 $18,238 $123 $34–$988 $163
2020 $9,518 $90 $29–$627 $114
2021 $9,965 $82 $21–$371 $132
2022 $1,593 $97 $27–$459 $149
2023 $0 $119 $25–$623 $160
2024 $11,851 $113 $27–$738 $164
2025 $118 $119 $39–$763 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genentech USA, Inc. $14,674 11 payments
  2. Merck Sharp & Dohme Corporation $14,004 19 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $10,585 10 payments
  4. Illumina, Inc. $6,237 5 payments
  5. AstraZeneca Pharmaceuticals LP $5,733 12 payments
  6. Genentech, Inc. $50 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $35,822 21 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,778 3 payments
  3. Travel and Lodging $4,782 15 payments
  4. Food and Beverage $849 17 payments
  5. Education $50 1 payment
  6. Gift $3 1 payment
Products named General payments · program years 2019–2025
  1. Vitrakvi $10,585 10 payments
  2. Oncology Testing $6,237 5 payments
  3. Avastin $4,436 4 payments
  4. ROZLYTREK $3,982 3 payments
  5. IMFINZI $3,531 3 payments
  6. Herceptin $2,616 3 payments
  7. Rituxan $2,616 3 payments
  8. Tamiflu $2,616 3 payments
  9. Lucentis $2,616 3 payments
  10. Tarceva $1,820 1 payment
  11. Other $1,415 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

58 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record